Pharmacogenomics (PGx) Market Size, Analysis | Industry Report, 2026

1. Welcome To Dataintelo

2. Pharmacogenomics (PGx) Market Size, Analysis | Industry Report, 2026 • The global pharmacogenomics (PGx) market size is expected to increase at a significant CAGR during the forecast period, 2020–2026. Pgx is the study of drug interaction with an individual’s genes. The applied science helps understand how medications affect an individual’s inherent genes. Growth in the demand for personalized drugs, rise in the usage of drug discovery processes, growth in the prevalence of several infectious and non-infectious diseases, and increase in awareness regarding the benefits of PGx are fueling its demand.

3. Market Trends, Drivers, Restraints, and Opportunities: • Technological developments in the field of applied science are major factors driving the market. For example, the SmatAmp method helps in the detection of mutation or genetic polymorphism without PCR amplification and DNA isolation. • Government regulations and standards are expected to propel the growth of this market. • High costs associated with capital investments and processing for R&D of PGx investigation is likely to hamper market growth. • Demand for PGx is increasing due to factors such as increase in the foreign direct investment (FDI), rise in medical tourism, and globalization are boosting the growth of PGx in drug delivery systems and developments in pharmaceutical and biopharmaceutical companies.

4. Scope of the report:

5. Pharmacogenomics (PGx) Market Segment Insights: Diagnostic tests segment is expected to generate large revenue Based on types, the market has been bifurcated into therapeutic tests and diagnostic tests. The diagnostic tests segment is expected to generate large revenue due to its accuracy, which helps medical professionals identify the root cause of the problem or a disease. A diagnostic test is performed to identify the responsible factors behind the problem and therapeutic tests are conducted to confirm the treatment for a health problem or disease. Polymerase chain reaction segment leads the market In terms of technology, the market has been segregated sequencing, polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others. The PCR segment leads the market. It generated large revenue in 2019 and this trend is expected to continue during the forecast period due to increasing technological advancements, rising global healthcare expenditure, and growing R&D investments.

6. Oncology segment held a large share of the market On the basis of applications, the market has been classified as oncology, infectious diseases, and cardiovascular. The oncology segment held a large share of the global market due to factors such as growing geriatric population and rising prevalence of cancer across the globe. Market in Asia Pacific is estimated to expand at a substantial pace in the coming years. Based on regions, the global pharmacogenomics (PGx) market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in Asia Pacific is anticipated to grow considerably in the coming years owing to factors such as increase in FDI in major countries of the region.

7. Competitive Landscape: Major companies in the pharmacogenomics (PGx) market include Laboratory Corporation of America Holdings, Illumina, Inc., Genomic Health, Inc., geneOmbio Technologies Pvt. Ltd., F. Hoffmann-La Roche Ltd, Dynamic DNA Laboratories, Cancer Genetics, Inc., Agena Biosciences, Inc., Admera Health, LLC, and Abbott Laboratories. Leading companies implement numerous strategic initiatives such as product launches, acquisitions, agreements, collaborations, technological upgrade, mergers, and partnerships to gain market share and sustain the competition in the market. For instance, Bio therapeutics (BTs) is one of the recent, trending, and fastest growing technologies for drug molecules, which offer several advantages over traditional pharmaceuticals small molecule techniques due to their relatively low off-target effects, high specificity, and biocompatible metabolism. Their utility; however, is limited by their variable therapeutic efficacy and high immunogenic potential. Segments Covered in the Report • The global pharmacogenomics (PGx) market has been segmented based on materials, applications, end-users, and regions.

8. By Types • Therapeutic Tests • Diagnostic Tests By Technologies • Sequencing • Polymerase Chain Reaction • Gel Electrophoresis • Mass Spectrometry • Microarray • Others By Applications • Oncology • Infectious Diseases • Cardiovascular By Regions • North America • Europe • Asia Pacific • Latin America • Middle East & Africa

9. Thank You